New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
10 mars 2025 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
-- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology...
LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
25 févr. 2025 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE...
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
13 févr. 2025 10h35 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced...
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11 févr. 2025 08h42 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced...
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
10 févr. 2025 17h00 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced...
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
04 sept. 2024 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
26 août 2024 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new...
LIXTE Biotechnology Provides Update On Recent Activities and Developments
19 août 2024 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- ...
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
15 août 2024 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference- PASADENA, CALIF., Aug. 15, 2024 ...
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
14 juin 2024 11h00 HE
|
Lixte Biotechnology Holdings, Inc.
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE...